Lecanemab for Alzheimer's disease at different doses
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether the drug lecanemab works better at different doses for people with early Alzheimer's disease or mild cognitive impairment caused by Alzheimer's. It aims to see if the drug can slow memory loss in real-world situations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of mild cognitive impairment (MCI) or mild Alzheimer's disease, confirmed by a special brain scan (PIB-PET positive).
- You are between 50 and 85 years old.
- You are not currently in another research study.
- You can understand and follow study instructions and give written permission to participate.
- You do not have other causes of memory problems, like stroke, Lewy body dementia, or depression.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
This trial tests a monoclonal antibody therapy—a lab-made protein—to see if it can slow Alzheimer's symptoms. You may qualify if you have early Alzheimer's or mild cognitive impairment with a positive PET scan, and you can't have other major health issues like uncontrolled diabetes or heart problems.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
Hear when a new MCI-AD, Early Stage Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.